Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 8Neoplasms 7Colorectal Neoplasms 5Recurrence 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Radiation Pneumonitis 2Peritoneal Neoplasms 2Mesothelioma, Malignant 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasm Metastasis 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × nintedanib × Clear all
NCT07485920 2026-03-20

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

The Affiliated Hospital of Qingdao University

Phase 4 Not yet recruiting
20 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01441297 2017-08-25

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
24 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02152059 2016-07-06

A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

AHS Cancer Control Alberta

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡